Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 7Pancreatic Neoplasms 1Liver Neoplasms 1Digestive System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Advanced Solid Tumor 1

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × donafenib × Clear all
NCT04059874 2019-08-16

Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

First Affiliated Hospital of Zhejiang University

Phase 1 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡